Technology areas: Biotechnology & Pharmaceuticals • Computing & Software
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
20/20 Genesystems currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. The portfolio exhibits a high degree of fragmentation, as these actions are spread across 3 distinct examiners and 3 distinct art units. This arrangement suggests that each pending matter is being evaluated independently within the USPTO's life sciences divisions. Such a spread indicates that the company's patenting efforts are not concentrated under a single technical or administrative path.
FLINDERS, JEREMY C is identified as the busiest examiner for the company, though they are responsible for 1 pending office action. Because the 3 pending actions are divided among 3 distinct examiners, no single examiner holds a majority of the active workload. This distribution across 3 distinct art units may reflect a broad research and development focus within the company's biotechnology patenting efforts. For the company, this means that prosecution strategies must be tailored to 3 different sets of examiner expectations and art unit guidelines. The presence of 3 distinct examiners ensures that the portfolio's outcomes are not dependent on any single individual's review.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FLINDERS, JEREMY C | 1 | 63.5% | +17.0% |
| VINCENT, DAVID ROBERT | 1 | 80.4% | +3.8% |
| MINCHELLA, KAITLYN L | 1 | 26.4% | +21.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18005560 | UNIVERSAL PAN CANCER CLASSIFIER MODELS, MACHINE LEARNING SYSTEMS AND METHODS OF USE | VINCENT, DAVID ROBERT | 54d |
| 18007725 | METHODS AND SOFTWARE SYSTEMS TO OPTIMIZE AND PERSONALIZE THE FREQUENCY OF CANCER SCREENING BLOOD TESTS | MINCHELLA, KAITLYN L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18451792 | METHODS AND ALGORITHMS FOR AIDING IN THE DETECTION OF CANCER | FLINDERS, JEREMY C | — |
| 18007725 | METHODS AND SOFTWARE SYSTEMS TO OPTIMIZE AND PERSONALIZE THE FREQUENCY OF CANCER SCREENING BLOOD TESTS | MINCHELLA, KAITLYN L | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| 2123 | 1 |
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18451792 | METHODS AND ALGORITHMS FOR AIDING IN THE DETECTION OF CANCER | FLINDERS, JEREMY C | 1684 | §112DP | Non-Final OA | — | Pending | Aug 17, 2023 |
| 18005560 | UNIVERSAL PAN CANCER CLASSIFIER MODELS, MACHINE LEARNING SYSTEMS AND METHODS OF USE | VINCENT, DAVID ROBERT | 2123 | §101§103 | Final Rejection | 54d | Pending | Jan 13, 2023 |
| 18007725 | METHODS AND SOFTWARE SYSTEMS TO OPTIMIZE AND PERSONALIZE THE FREQUENCY OF CANCER SCREENING BLOOD TESTS | MINCHELLA, KAITLYN L | 1685 | §103§112 | Final Rejection | — | Pending | Dec 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial20/20 Genesystems has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Jeremy C Flinders has the most, with 1 of 20/20 Genesystems's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
